**Review of Linezolid**

**Abstract :** Linezolid may have been the first antibiotic in the class of oxazolidinone antibiotics. This substance is a synthetic antibiotic that binds to rRNA to prevent bacteria from synthesising proteins. Additionally, it suppresses the initiation complex's formation during protein synthesis, which can shorten formed peptide chains and slow down the rate at which translation elongation occurs. Linezolid has been shown to bind a deep cleft of the 50S ribosomal subunit that is surrounded by 23S rRNA nucleotides through analysis of high-resolution structures of the drug. It has been demonstrated that 23S rRNA mutations cause linezolid resistance. More recent antibiotics that target resistant Gram-positive bacteria include linezolid, a synthetic oxazolidinone. Since 2000, linezolid has been widely accessible for the treatment of Gram-positive infections and is effective against a variety of Gram-positive bacteria.

**Key words :** Linezolid, Mode of action, Pharmacokinetic, Drug interactions, Microbiological activity, Administration

**Introduction :**

Among the oxazolidinone antibiotic class, linezolid is regarded as the pioneer member. Because of their efficacy in managing plant diseases, oxazolidinones were initially introduced in 1978. It was discovered six years later that these compounds have antibacterial qualities that were noticeably better than those of their parent compounds.1 Known as the first genuine lead compounds in the oxazolidinone family, these oxazolidinone compounds.

A chemical that exhibits pharmacological characteristics that suggest the compound's potential as a foundational material for therapeutic development is known as a lead compound.2According to research by Barbachyn et al., additional structural debate resulted in the creation of piperazine derivatives utilising lead compounds.2 Due to their exceptional antibacterial activity and acceptable safety profile, these compounds were chosen for additional modification. Linezolid was first made available in 1996 after thorough testing at Pharmacia3, where it was later shown to be a lead compound. In 2000, the US Food and Drug Administration authorised linezolid. Over the past forty years, oxazolidinones—which are being utilised in clinics—have gained attention as a genuinely novel class of antibiotics.4

**Structure–activity relationship of Linezoild**

Studies on the link between structure and activity in oxazolidinones showed that the 5-S configuration and N-aryl group are critical to the activity. The action is due to the 5-acylaminomethyl group. It has been demonstrated that the aryl ring's electron-withdrawing group increases activity. While additional substituents on the proximal aromatic ring can alter solubility and pharmacokinetics, they have no effect on antibacterial efficacy.5

 

**Fig 1: Structure of Linezolid**

**Mode of action**

According to Figure 2, oxazolidinones attach to the bacterial ribosome's 50S subunit and stop it from complexing with mRNA, initiation factors, 30S subunit, and formylmethionyl-tRNA.6.7 As a result, translation of the mRNA is inhibited by blocking the assembly of a functional initiation complex for protein synthesis. The current class of protein synthesis inhibitors, which include macrolides, lincosamides, tetracyclines, and chloramphenicol, permits mRNA translation to start but inhibits peptide elongation, has a different mechanism of action than this one. Although this difference might appear intellectual, it could be important in two ways. Because of this mode of action, clotting factors, hemolysins, and protein A are examples of staphylococcal and streptococcal virulence factors that appear to be particularly effective in blocking the production of linezolid.8 Second, the target of linezolid does not overlap with that of the currently available inhibitors of protein synthesis; as a result, the rRNA methylases that alter 23S rRNA to prevent the binding of macrolides, clindamycin, and group B streptogramins do not influence linezolid's efficacy.

Preventing peptide elongation is not intrinsically more deadly than preventing the start of protein synthesis. As a result, linezolid shares many bacteriostatic properties with clindamycin, macrolides, tetracyclines, and chloramphenicol. The aminoglycosides are the only protein synthesis inhibitors that exhibit potent bactericidal activity. They work by misreading mRNA, which results in the creation of faulty proteins that, among other things, destabilise the membrane structure and allow cell contents to seep out. While the ribosomes of Gram-positive cocci are equally sensitive to linezolid, Gram-negative bacteria exhibit resistance to oxazolidinones, with a few minor exceptions listed below. This resistance is likely due to the recognition and excretion of oxazolidinones by endogenous efflux pumps.6



**Fig.2: Mode of action of the oxazolidinones**

**Pharmacokinetics**

**Absorption:** With an absolute bioavailability of almost 100%, linezolid is well absorbed when taken orally. Food delays the rate but not the extent of oral absorption, therefore the medication can be given orally or intravenously without requiring a change in dosage.7

**Distribution:** With a roughly 31% plasma protein binding, linezolid spreads easily to well-perfused tissues. In healthy adults, the volume of distribution (Vd) at steady-state is roughly 40 to 50 litres. Because it may penetrate the blood-brain barrier, linezolid is a great treatment for MRSA-caused CNS infections.8 The research discovered that in nearly all patients with drug-resistant tuberculosis, linezolid concentrations in the lung remained above the minimum inhibitory concentration (MIC) and mutation prevention concentration (MPC) values, even if these concentrations were lower in the lung than in the serum.9

**Metabolism:** The morpholine ring of linezolid is oxidised, producing two inactive carboxylic acid metabolites (A and B). Metabolite B is created via a non-enzymatic chemical oxidation process, whereas metabolite A is synthesised enzymatically.

**Excretion:** About 40 mL/min of renal clearance indicates tubular reabsorption. About 30% of the dose is excreted in the urine as linezolid under steady-state circumstances, and the remaining 40% and 10% are removed as metabolites A and B, respectively. Patients with renal impairment may have an accumulation of linezolid metabolites.10

**Drug interactions**

The body may respond differently to a medication when it is given in combination with another medication. Such an interaction could have negative effects or delay, reduce, or raise the absorption of one or both medications.11–13

It is safe to combine linezolid with aztreonam; however, there is insufficient data to determine how linezolid and rifampin interact.14 There were no harmful effects from co-administration of ceftazidime, ciprofloxacin, meropenem, and gentamicin with Gram-negative antibiotics. Furthermore, the sufficiency of antifungal medications such as aminoglycosides, β-lactams, amphotericin B and azoles, fluoroquinolones, and aminoglycosides was not affected by the use of linezolid in combination with them. Thus, it appears that there will be no interactions when using linezolid with other antimicrobials.14

Due to its nonspecific inhibition of monoamine oxidase, linezolid when coupled with serotonin reuptake inhibitors might result in potentially fatal serotonin poisoning.15,16 Findings suggest that linezolid is not contraindicated in this condition, however clinicians should be aware of this potentially serious interaction and closely monitor patients who are given linezolid in combination with serotonergic therapies.17

**Microbiological activity**

A variety of Gram-positive aerobic bacteria18 and certain Gram-positive anaerobes, such as Actinomyces spp., are susceptible to the action of linezolid. Additionally, it has the ability to combat several Mycobacterial species, some Gram-negative anaerobic bacteria, and Nocardia spp.

**Gram-positive aerobic bacteria**

Penicillin-resistant pneumococci (PRP), vancomycin-resistant enterococci (VRE), and other resistant strains of many types of Gram-positive anaerobic bacteria are among the many bacteria that linezolid effectively combats.
Compared to S. aureus species, the minimum inhibitory concentrations (MICs) of coagulase-negative staphylococci (CoNS) to linezolid are often lower.Whether a strain of S. aureus or CoNS is resistant or sensitive to methicillin has no effect on its 19 MICs to linezolid:20 There is no correlation between staphylococcal species' reduced susceptibility to linezolid and vancomycin.21

Many streptococci, such as entrococci, viridians streptococci, and group A, B, C, F, and G β-hemolytic streptococci, are active against linezolid.22-24 The majority of streptococci have MICs of up to 2 mcg/mL, while some strains of viridians and group A streptococci have been reported to have MICs of up to 4 mcg/mL25 PRP are still vulnerable to linezolid.26 VRE and enterococci susceptible to vancomycin share MICs with linezolid.Linezolid is effective against 19,20 Corynebacterium species, Listeria monocytogenes, Bacillus species, Rhodococcus equi, Nocardia species, and many Lactobacillus species.23, 27-30

**Anaerobic bacteria**

Linezolid is effective against a number of Gram-positive and Gram-negative anaerobic bacteria, such as numerous strains of Clostridium difficile,31,32 Fusobacterium spp.,33 Prevotella spp.,34 and Bacteroides spp. 35Some Actinomyces spp. strains are susceptible to the effects of linezolid.36

**Mycobacteria**

Linezolid exhibits efficacy against many atypical mycobacteria and Mycobacterium tuberculosis. Linezolid can often be used to treat slow-growing mycobacteria, while some, including M. avium Complex (MAC), are typically resistant.37
Atypical mycobacteria that grow quickly are less vulnerable, and MICs must be ascertained.38

**Applications of linezolid**

The Food and Drug Administration has authorised the use of linezolid in the following conditions: Hospital-acquired pneumonia

(a): caused by Streptococcus pneumoniae, including multidrug-resistant strains;

(b): vancomycin-resistant Enterococcus faecium (VREF) infections, including cases with concurrent bacteremia;

 (c): complicated skin and skin structure infections (SSSIs), including diabetic foot infections (DFIs) without concurrent osteomyelitis, caused by Streptococcus aureus (MSSA and MRSA);

(d): caused by MSSA or S. pyogenes;

(e): community-acquired pneumoniae, including cases with simultaneous bacteremia, or MSSA; and

(f): pneumococcal meningitis caused by penicillin-resistant streptococcus aureus

**Administration**

**Available Dosage Forms and Strengths**

Linezolid is available in tablets, suspension, and injection. The dosage of intravenous (IV) and tablet formulations are interchangeable. Renal dosing is not required. Invert gently to mix before administration, and do not vigorously shake the oral suspension. Linezolid is available as an injectable solution at a concentration of 2 mg/mL, an oral suspension of 100 mg/5 mL, and tablets containing 600 mg.

Administer linezolid IV infusion over 30 to 120 minutes. Do not mix or infuse with other medications. When using the same IV line for sequential infusion, flush the line with D5W, normal saline, or lactated Ringer's solution before and after infusing linezolid. The yellow color of the injection may intensify with time without affecting potency. Linezolid use may result in a suboptimal clinical response when treating organisms with a MIC (minimum inhibitory concentration) of 4 mcg/ml or greater and warrants a complete infectious disease re-assessment and change in drug therapy.

**Adult Dosage**

**Nosocomial pneumonia**

* Dose: The recommended dose for nosocomial pneumonia is 600 mg, administered IV or orally every 12 hours.
* Duration: Treatment is typically continued for 10 to 14 days.

**Community-acquired pneumonia with concurrent bacteremia**

* Dose: The recommended dose of community-acquired pneumonia with concurrent bacteremia is 600 mg administered IV or orally every 12 hours.
* Duration: Treatment usually continues for 10 to 14 days.

**Complicated skin and skin structure infections**

* Dose: In complicated skin and soft tissue infections (cSSTIs), the recommended linezolid dosage is 600 mg IV or orally every 12 hours.
* Duration: Treatment typically is for 10 to 14 days.

**Uncomplicated skin and skin structure infections**

* Dose: Adults should take a dose of 400 mg orally every 12 hours.
* Duration: Treatment typically is for 10 to 14 days.

**Vancomycin-resistant*Enterococcus faecium* infections, including concurrent bacteremia**

* Dose: The recommended dose for vancomycin-resistant *Enterococcus faecium* infections, including concurrent bacteremia, is 600 mg administered IV or orally every 12 hours.
* Duration: Treatment is extended for a period of 14 to 28 days.

**Specific Patient Populations**

**Hepatic impairment**: Linezolid pharmacokinetics remain unchanged in mild-to-moderate hepatic impairment (Child-Pugh class A or B), and no dosage adjustment is recommended. The risk of hematological toxicity increases in patients with cirrhosis.

**Renal impairment:** Use linezolid with caution in renal impairment due to the risk of thrombocytopenia.

**Breastfeeding considerations:** Linezolid is excreted into breast milk at concentrations likely to be effective against staphylococcal strains commonly found in mastitis. Limited clinical data suggest that infants would receive 6% to 9% of the standard infant dose through breast milk; thus, monitoring the infant for potential gastrointestinal effects, such as diarrhea and vomiting, is advisable. Due to limited published experience with linezolid during breastfeeding, an alternative drug may be preferred, especially when nursing a newborn or preterm infant.

**Pregnancy considerations:** A lack of pharmacokinetic and controlled studies of linezolid are available in pregnant women. A case report demonstrated positive maternal outcomes without fetal teratogenesis during a 4-week course of linezolid initiated at the 14th week of pregnancy. Linezolid could be used during pregnancy when the potential benefits outweigh the risks. Linezolid has also been used in pregnancy for multidrug resistant tuberculosis (MDR-TB); however, clinicians should monitor for adverse effects. Animal studies indicate that higher doses in mice resulted in maternal toxicity, increased embryo death, and decreased fetal body weights, with costal cartilage fusion. Reduced fetal body weights and decreased ossification of sternebrae at the higher dose were seen in rats.

**Pediatric patients**

**Nosocomial pneumonia:**

* Dose: The recommended dose for nosocomial pneumonia is 10 mg/kg IV or orally every 8 hours.
* Duration: Treatment is typically continued for 10 to 14 days.

**Community-acquired pneumonia with concurrent bacteremia:**

* Dose: The recommended dose for community-acquired pneumonia with concurrent bacteremia is 10 mg/kg IV or orally every 8 hours.
* Duration: Treatment usually continues for 10 to 14 days.

**Complicated skin and skin structure infections:**

* Dose: In complicated skin and soft tissue infections (cSSTIs), the linezolid dosage is 10 mg/kg IV or orally every 8 hours.
* Duration: Treatment typically is for 10 to 14 days.

**Uncomplicated skin and skin structure infections:**

* Dose: For uncomplicated skin and skin structure infections, children aged less than 5 should be prescribed 10 mg/kg orally every 8 hours. Children aged 5 to 11 should be prescribed 10 mg/kg orally every 12 hours.
* Duration: Treatment typically is for 10 to 14 days.

**Vancomycin-resistant*Enterococcus faecium* infections, including concurrent bacteremia:**

* Dose: The recommended dose for vancomycin-resistant *Enterococcus faecium* infections, including concurrent bacteremia, is 10 mg/kg IV or orally every 8 hours
* Duration: Treatment is extended for a period of 14 to 28 days.

**Older patients:** Clinical studies did not reveal significant disparities in the safety or effectiveness of linezolid between older and younger patients. However, increased sensitivity to linezolid in older patients is possible.

**Adverse Effects**

The most common adverse effects experienced with linezolid use include decreased platelets, hemoglobin, white blood cell counts, headache, nausea, diarrhea, elevated pancreatic enzymes, elevated liver function tests, and neuropathy. Warnings associated with linezolid include duration-related myelosuppression (thrombocytopenia, anemia, leukopenia), serotonin syndrome, hypoglycemia; caution in patients on insulin or hypoglycemic drugs, seizures, lactic acidosis, hypertension when used with adrenergic drugs, and irreversible peripheral and optic neuropathy when used for 28 days or greater. Reports exist of blurred vision in patients receiving shorter courses of linezolid. Prolonged use may result in fungal or bacterial infection, including *Clostridioides difficile*-associated diarrhea (CDAD) and pseudomembranous colitis. CDAD can occur greater than 2 months after postantibiotic treatment. Lactic acidosis may also occur with use; evaluate patients who develop recurrent nausea and vomiting, unexplained acidosis, or low bicarbonate concentrations.

**Drug-Drug Interactions**

**Adrenergic drugs:** Avoid using linezolid with adrenergic drugs such as pseudoephedrine, epinephrine, norepinephrine, dopamine, or dobutamine due to the risk of hypertensive crisis.

**Serotonergic drugs:** Serotonin syndrome can occur when linezolid is co-administered with serotonergic agents such as SSRI. Therefore, linezolid should not be used with patients taking serotonergic antidepressants or other medications like tricyclic antidepressants, bupropion, buspirone, triptans, or meperidine unless clinically necessary and closely monitored for signs of serotonin syndrome or neuroleptic malignant syndrome. If urgent linezolid treatment is required for patients already taking serotonergic drugs, discontinue the antidepressant and administer linezolid. Monitor for 2 weeks and up to 5 weeks with fluvoxamine.

**Myelosuppressive agents:** Linezolid should be cautiously used with drugs that can cause bone marrow suppression. Concurrent administration of linezolid with drugs such as clozapine and cladribine should be avoided.

**Referance:**

1.Ford CW, Zurenko GE, Barbachyn MR. The discovery of linezolid, the first oxazolidinone antibacterial agent. Curr Drug Targets Infect Disord. 2001;1(2):181–199.

2.Barbachyn MR, Toops DS, Grega KC, et al. Synthesis and antibacterial activity of new tropone-substituted phenyloxazolidinone antibacterial agents 2. Modification of the phenyl ring – the potentiating effect of fluorine substitution on in vivo activity. Bioorg Med Chem Lett. 1996;6(9): 1009–1014

 3. Zyvox [package insert]. Kalamazoo, MI: Pharmacia-Upjohn; 2004.

 4. Watkins RR, Lemonovich TL, File TM Jr. An evidence-based review of linezolid for the treatment of methicillin-resistant Staphylococcus aureus (MRSA): place in therapy. Core Evid. 2012;7:131–143

5. Poce G, Cocozza M, Consalvi S, Biava M. SAR analysis of new anti-TB drugs currently in pre-clinical and clinical development. Eur J Med Chem. 2014;86:335–351.

6. Swaney, S. M., Aoki, H., Ganoza, M. C. & Shinabarger, D. L.(1998). The oxazolidinone linezolid inhibits initiation of protein synthesis in bacteria.

Antimicrobial Agents and Chemotherapy 42,3251–5.

7.Norrby R. Linezolid--a review of the first oxazolidinone. Expert Opin Pharmacother. 2001 Feb;2(2):293-302.

8.Chen HA, Yang CJ, Tsai MS, Liao CH, Lee CH. Linezolid as salvage therapy for central nervous system infections due to methicillin-resistant Staphylococcus aureus at two medical centers in Taiwan. J Microbiol Immunol Infect. 2020 Dec;53(6):909-915.

9.Kempker RR, Heinrichs MT, Nikolaishvili K, Sabulua I, Bablishvili N, Gogishvili S, Avaliani Z, Little BP, Bernheim A, Derendorf H, Blumberg HM, Vashakidze S, Peloquin CA. A comparison of linezolid lung tissue concentrations among patients with drug-resistant tuberculosis. Eur Respir J. 2018 Feb;51(2)

10.Dryden MS. Linezolid pharmacokinetics and pharmacodynamics in clinical treatment. J Antimicrob Chemother. 2011 May;66 Suppl 4:iv7-iv15.

11. Farhadi T. In silico designing of peptide inhibitors against pregnane X receptor: the novel candidates to control drug metabolism. Int J Pept Res Ther. Epub 2017 Aug 31.

12. Farhadi T, Fakharian A, Ovchinnikov RS. Virtual screening for potential inhibitors of CTX-M-15 protein of Klebsiella pneumoniae. Interdiscip Sci. Epub 2017 Apr 3.

13. Wankhade G, Kamble S, Deshmukh S, Jena L, Waghmare P, Harinath BC. Inhibition of mycobacterial CYP125 enzyme by sesamin and β-sitosterol:an in silico and in vitro study. Biomed Biotechnol Res J. 2017;1:49–54.

14. Vinh DC, Rubinstein E. Linezolid: a review of safety and tolerability. J Infect. 2009;59 Suppl 1:S59–S74.

15. Gillman PK. Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity. Br J Anaesth. 2005;95(4):434–441.

16. Frykberg RG, Gordon S, Tierney E, Banks J. Linezolid-associated serotonin syndrome. A report of two cases. J Am Podiatr Med Assoc. 2015;105(3):244–248.

17. Woytowish MR, Maynor LM. Clinical relevance of linezolid-associated serotonin toxicity. Ann Pharmacother. 2013;47(3):388–397

18. Mouton JW, Jansz AR. The DUEL study:a multi-center in vitro evaluation of Linezolid compared with other antibiotics in The Netherlands. Clin Microbiol Infect. 2001;7(9):486–491.

19. Draghi DC, Sheehan DJ, Hogan P, Sahm DF. In vitro activity of linezolid against key gram-positive organisms isolated in the united states:results of the LEADER 2004 surveillance program. Antimicrob Agents Chemother. 2005;49(12):5024–5032.

20. Mutnick AH, Biedenbach DJ, Turnidge JD, Jones RN. Spectrum and potency evaluation of a new oxazolidinone, linezolid: report from the SENTRY Antimicrobial Surveillance Program, 1998–2000. Diagn Microbiol Infect Dis. 2002;43(1):65–73.

21. Jevitt LA, Smith AJ, Williams PP, Raney PM, McGowan JE Jr, Tenover FC. In vitro activities of Daptomycin, Linezolid, and Quinupristin-Dalfopristin against a challenge panel of Staphylococci and Enterococci, including vancomycin-intermediate staphylococcus aureus and vancomycin-resistant Enterococcus faecium. Microb Drug Resist. 2003;9(4):389–393.

22. Fluegge K, Supper S, Siedler A, Berner R. Antibiotic susceptibility in neonatal invasive isolates of Streptococcus agalactiae in a 2-year nationwide surveillance study in Germany. Antimicrob Agents Chemother. 2004;48(11):4444–4446.

23. Jones RN, Stilwell MG, Hogan PA, Sheehan DJ. Activity of linezolid against 3,251 strains of uncommonly isolated gram-positive organisms: report from the SENTRY Antimicrobial Surveillance Program. Antimicrob Agents Chemother. 2007;51(4):1491–1493.

24. Betriu C, Redondo M, Palau ML, et al. Comparative in vitro activities of linezolid, quinupristin dalfopristin, moxifloxacin, and trovafloxacin against erythromycin-susceptible and -resistant streptococci. Antimicrob Agents Chemother. 2000;44(7):1838–1841.

25. Kosowska-Shick K, Smith K, Bogdanovich T, Ednie LM, Jones RN, Appelbaum PC. Activity of DX-619 compared to other agents against viridans group streptococci, Streptococcus bovis, and Cardiobacterium hominis. Antimicrob Agents Chemother. 2006;50(12):4191–4194.

26. Zhanel GG, Palatnick L, Nichol KA, Bellyou T, Low DE, Hoban DJ. Antimicrobial resistance in respiratory tract Streptococcus pneumoniae isolates: results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002. Antimicrob Agents Chemother. 2003;47(6):1867–1874.

27. Funke G, Nietznik C. Minimal inhibitory concentrations of linezolid against clinical isolates of coryneform bacteria. Eur J Clin Microbiol Infect Dis. 2005;24(9):612–614.

28. Klare I, Konstabel C, Werner G, et al. Antimicrobial susceptibilitiesof Lactobacillus, Pediococcus and Lactococcus human isolates and cultures intended for probiotic or nutritional use. J Antimicrob Chemother. 2007;59(5):900–912.

29. Bowersock TL, Salmon SA, Portis ES, et al. MICs of oxazolidinones for Rhodococcus equi strains isolated from humans and animals. Antimicrob Agents Chemother. 2000;44(5):1367–1369.

30. Brown-Elliott BA, Ward SC, Crist CJ, Mann LB, Wilson RW, Wallace RJ Jr. In vitro activities of linezolid against multiple Nocardia species. Antimicrob Agents Chemother. 2001;45(4):1295–1297.

31. Ackermann G, Adler D, Rodloff AC. In vitro activity of linezolid against Clostridium difficile. J Antimicrob Chemother. 2003;51(3):743–745.

32. Baines SD, Noel AR, Huscroft GS, et al. Evaluation of linezolid for the treatment of Clostridium difficile infection caused by epidemic strains using an in vitro human gut model. J Antimicrob Chemother. 2011;66(7):1537–1546.

33. Daeschlein G, Hoehne C, Assadian O, et al. In vitro activity of linezolid against clinical isolates of Fusobacterium spp. J Antimicrob Chemother. 2006;58(4):789–793.

34. Citron DM, Merriam CV, Tyrrell KL, Warren YA, Fernandez H, Goldstein EJ. In vitro activities of ramoplanin, teicoplanin, vancomycin, linezolid, bacitracin, and four other antimicrobials against intestinal anaerobic bacteria. Antimicrob Agents Chemother. 2003;47(7):2334–2338.

35. Molitoris D, Väisänen ML, Bolaños M, Finegold SM. In vitro activities of DX-619 and four comparator agents against 376 anaerobic bacterial isolates. Antimicrob Agents Chemother. 2006;50(5):1887–1889.

36. Smith AJ, Hall V, Thakker B, Gemmell CG. Antimicrobial susceptibility testing of Actinomyces species with 12 antimicrobial agents. J Antimicrob Chemother. 2005;56(2):407–409.

37. Brown-Elliott BA, Crist CJ, Mann LB, Wilson RW, Wallace RJ Jr. In vitro activity of linezolid against slowly growing nontuberculous Mycobacteria. Antimicrob Agents Chemother. 2003;47(5): 1736–1738.

38. Yang SC, Hsueh PR, Lai HC, et al. High prevalence of antimicrobial resistance in rapidly growing mycobacteria in Taiwan. Antimicrob Agents Chemother. 2003;47(6):1958–1962.

39. Angela Azzouz; Charles V. Preuss, National library of Medicine , 2024